Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$251.65
+3.0%		$246.41
$197.81
▼
$495.55
$33.67B0.311.46 million shs1.13 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$69.23
+4.0%		$78.98
$48.78
▼
$93.42
$13.53B0.972.90 million shs3.74 million shs
Biogen Inc. stock logo
BIIB
Biogen
$225.36
+2.9%		$211.20
$135.39
▼
$226.43
$33.30B0.171.20 million shs1.11 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$192.86
+0.1%		$199.74
$42.18
▼
$224.31
$41.34B1.42.92 million shs1.88 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+1.99%-2.27%+3.43%-15.22%-46.13%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.05%-8.01%-18.31%-2.99%+27.13%
Biogen Inc. stock logo
BIIB
Biogen
+1.66%+0.79%+1.06%+11.10%+53.73%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+0.95%-6.02%-7.97%+13.72%+342.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$251.65
+3.0%		$246.41
$197.81
▼
$495.55
$33.67B0.311.46 million shs1.13 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$69.23
+4.0%		$78.98
$48.78
▼
$93.42
$13.53B0.972.90 million shs3.74 million shs
Biogen Inc. stock logo
BIIB
Biogen
$225.36
+2.9%		$211.20
$135.39
▼
$226.43
$33.30B0.171.20 million shs1.11 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$192.86
+0.1%		$199.74
$42.18
▼
$224.31
$41.34B1.42.92 million shs1.88 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+1.99%-2.27%+3.43%-15.22%-46.13%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.05%-8.01%-18.31%-2.99%+27.13%
Biogen Inc. stock logo
BIIB
Biogen
+1.66%+0.79%+1.06%+11.10%+53.73%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+0.95%-6.02%-7.97%+13.72%+342.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.87
Moderate Buy$367.2045.92% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$102.6148.22% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.58
Moderate Buy$230.142.12% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.95
Moderate Buy$228.2118.33% Upside

Current Analyst Ratings Breakdown

Latest BBIO, RVMD, ALNY, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$455.00
9/21/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$225.00 ➝ $265.00
9/10/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D)
9/10/2026
Biogen Inc. stock logo
BIIB
Biogen
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$242.00
9/10/2026
Biogen Inc. stock logo
BIIB
Biogen
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetReduce$165.00 ➝ $175.00
9/10/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold ➝ Overweight$255.00
9/10/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/9/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$215.00 ➝ $230.00
9/8/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$230.00 ➝ $260.00
9/3/2026
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$225.00 ➝ $245.00
9/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$4.80B7.01$2.94 per share85.68$5.97 per share42.15
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M26.96N/AN/A($10.77) per share-6.43
Biogen Inc. stock logo
BIIB
Biogen
$10.03B3.32$23.67 per share9.52$124.45 per share1.81
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,569.74N/AN/A$8.44 per share22.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3846.7825.94N/A15.26%84.93%14.30%10/29/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6539.8913.992.388.32%11.18%6.88%10/28/2026 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%11/4/2026 (Estimated)

Latest BBIO, RVMD, ALNY, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
7/30/2026Q2 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.63$1.84+$0.21$1.21$1.32 billion$1.29 billion
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839195.49 million167.67 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
883214.34 million198.05 millionOptionable

Recent News About These Companies

44,928 Shares in Revolution Medicines, Inc. $RVMD Acquired by Nykredit A S
September 22 at 3:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-44928-shares-in-revolution-medicines-inc-rvmd-acquired-by-nykredit-a-s-2026-09-22/
Bank of America Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock
September 21 at 1:53 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-bank-of-america-forecasts-strong-price-appreciation-for-revolution-medicines-nasdaq-rvmd-stock-2026-09-21/
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $67,940.84 in Stock
September 21 at 5:10 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036626
Revolution Medicines (NASDAQ:RVMD) Insider Sells $2,786,969.12 in Stock
September 21 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036319
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $1,109,567.56 in Stock
September 21 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036313
Insider Selling: Revolution Medicines (NASDAQ:RVMD) COO Sells $989,625.08 in Stock
September 21 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036318
Revolution Medicines (NASDAQ:RVMD) CFO Sells $807,519.72 in Stock
September 21 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036311
Revolution Medicines, Inc.(NasdaqGS:RVMD) added to FTSE All-World Index
September 21 at 2:34 AM  |  marketscreener.comM
Revolution Medicines, Inc.(NasdaqGS:RVMD) added to FTSE All-World Index
September 21 at 2:34 AM  |  marketscreener.comM
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 341 Shares of Stock
September 19 at 7:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rvmd-insider-buying-and-selling-2026-09-19/
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Moderate Buy" from Analysts
September 19 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31032107
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Moderate Buy" from Analysts
September 19 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-revolution-medicines-inc-nasdaq-rvmd-receives-average-recommendation-of-moderate-buy-from-analysts-2026-09-19/
Alan Sandler Sells 341 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-alan-sandler-sells-341-shares-of-revolution-medicines-nasdaq-rvmd-stock-2026-09-18/
Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 4,053 Shares
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-revolution-medicines-nasdaq-rvmd-cfo-sells-4053-shares-2026-09-18/
Revolution Medicines (NASDAQ:RVMD) COO Sells 4,967 Shares of Stock
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-revolution-medicines-nasdaq-rvmd-coo-sells-4967-shares-of-stock-2026-09-18/
Stephen Michael Kelsey Sells 5,569 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-stephen-michael-kelsey-sells-5569-shares-of-revolution-medicines-nasdaq-rvmd-stock-2026-09-18/
Revolution Medicines (NASDAQ:RVMD) Insider Sells 13,988 Shares
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-revolution-medicines-nasdaq-rvmd-insider-sells-13988-shares-2026-09-18/
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
September 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/axsome-therapeutics-vs-revolution-medicines-130001677.html
983,911 Shares in Revolution Medicines, Inc. $RVMD Bought by Bank of America Corp DE
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-983911-shares-in-revolution-medicines-inc-rvmd-bought-by-bank-of-america-corp-de-2026-09-18/
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
September 17, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/17/revolution-medicines-just-hit-a-major-milestone-is-the-stock-a-buy/
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift
September 16, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/revolution-medicines-rvmd-promising-clinical-results-signal-potential-paradigm-shift-1838983/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Revolution Medicines logo displayed over a laboratory background with a microscope, flasks, and test tubes.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
By Chris Markoch | September 4, 2026
Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$251.65 +7.33 (+3.00%)
Closing price 04:00 PM Eastern
Extended Trading
$252.10 +0.45 (+0.18%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$69.23 +2.65 (+3.98%)
Closing price 04:00 PM Eastern
Extended Trading
$69.57 +0.34 (+0.49%)
As of 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Biogen stock logo

Biogen NASDAQ:BIIB

$225.36 +6.29 (+2.87%)
Closing price 04:00 PM Eastern
Extended Trading
$224.84 -0.52 (-0.23%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$192.86 +0.10 (+0.05%)
Closing price 04:00 PM Eastern
Extended Trading
$192.72 -0.14 (-0.07%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas